Abstract
Importance
The Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study showed that the addition of postnatal weight gain to birth weight and gestational age detects similar numbers of infants with ROP, but requires examination of fewer infants.
Objective
To determine the incremental cost-effectiveness of screening with G-ROP compared with conventional screening.
Design, setting and participants
We built a microsimulation model of a 1-year US birth cohort <32 weeks gestation, using data from the G-ROP study. We obtained resource utilization estimates from the G-ROP dataset and from secondary sources, and test characteristics from the G-ROP cohort.
Results
Among 78,281 infants nationally, screening with G-ROP detected ~25 additional infants with Type 1 ROP. This was accomplished with 36,233 fewer examinations, in 14,073 fewer infants, with annual cost savings of approximately US$2,931,980 through hospital discharge.
Conclusions
Screening with G-ROP reduced costs while increasing the detection of ROP compared with current screening guidelines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–94.
Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, et al. The incidence and course of retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity study. Pediatrics. 2005;116:15–23.
Palmer EA, Hardy RJ, Dobson V, Phelps DL, Quinn GE, Summers CG, et al. 15-year outcomes following threshold retinopathy of prematurity: final results from the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. Arch Ophthalmol. 2005;123:311–8.
Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142:e20183061.
Binenbaum G, Ying GS, Quinn GE, Huang J, Dreiseitl S, Antigua J, et al. The CHOP postnatal weight gain, birth weight, and gestational age retinopathy of prematurity risk model. Arch Ophthalmol. 2012;130:1560–5.
Binenbaum G, Ying GS, Tomlinson LA, Postnatal Growth and Retinopathy of Prematurity Study Group. Validation of the Children’s Hospital of Philadelphia Retinopathy of Prematurity (CHOP ROP) model. JAMA Ophthalmol. 2017;135:871–7.
Cao JH, Wagner BD, Cerda A, McCourt EA, Palestine A, Enzenauer RW, et al. Colorado retinopathy of prematurity model: a multi-institutional validation study. J Am Assoc Pediatr Ophthalmol Strabismus. 2016;20:220–5.
Eckert GU, Fortes Filho JB, Maia M, Procianoy RS. A predictive score for retinopathy of prematurity in very low birth weight preterm infants. Eye. 2012;26:400–6.
Lofqvist C, Hansen-Pupp I, Andersson E, Holm K, Smith LE, Ley D, et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol. 2009;127:622–7.
Wu C, Lofqvist C, Smith LE, VanderVeen DK, Hellstrom A, Consortium W. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol. 2012;130:992–9.
Binenbaum G, Bell EF, Donohue P, Quinn G, Shaffer J, Tomlinson LA, et al. Development of modified screening criteria for retinopathy of prematurity: primary results from the Postnatal Growth and Retinopathy of Prematurity Study. JAMA Ophthalmol. 2018;136:1034–40.
Quinn GE, Ying GS, Bell EF, Donohue PK, Morrison D, Tomlinson LA, et al. Incidence and early course of retinopathy of prematurity: secondary analysis of the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study. JAMA Ophthalmol. 2018;136:1383–9.
Dawson L, De Alba Campomanes A, Zupancic J, Binenbaum G. Time and motion study for retinopathy of prematurity examinations. J Am Assoc Pediatr Ophthalmol Strabismus. 2016;20:e14.
Bureau of Labor Statistics US Department of Labor. Occupational employment statistics: U.S. Government Printing Office. https://www.bls.gov/oes/current/oes_nat.htm#29-0000. Accessed March 4, 2019.
Doximity. 2018 Physician Compensation Report. Doximity: 2018. https://s3.amazonaws.com/s3.doximity.com/careers/2018_physician_compensation_report.pdf. Accessed March 4, 2019.
Kamholz KL, Cole CH, Gray JE, Zupancic JA. Cost-effectiveness of early treatment for retinopathy of prematurity. Pediatrics. 2009;123:262–9.
Bureau of Economic Analysis U.S. Department of Commerce. Price indexes for personal consumption expenditures by function 2018. https://apps.bea.gov/iTable/. Accessed March 4, 2019.
Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res. 2018;53:175–96.
United States Department of Health and Human Services (US DHHS) Centers for Disease Control and Prevention—National Center for Health Statistics (NCHS) Division of Vital Statistics. Natality Public-Use WONDER Online Database 2017. http://wonder.cdc.gov/natality-current.html. Accessed March 4, 2019.
Drummond M, Sculpher M, Klaxton C, Stoddart GL, Torrance G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015. p. 464.
Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779–87.
Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome–structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1990;108:1408–16.
Dunbar JA, Hsu V, Christensen M, Black B, Williams P, Beauchamp G. Cost-utility analysis of screening and laser treatment of retinopathy of prematurity. J Am Assoc Pediatr Ophthalmol Strabismus. 2009;13:186–90.
Jackson KM, Scott KE, Graff Zivin J, Bateman DA, Flynn JT, Keenan JD, et al. Cost-utility analysis of telemedicine and ophthalmoscopy for retinopathy of prematurity management. Arch Ophthalmol. 2008;126:493–9.
Rothschild MI, Russ R, Brennan KA, Williams CJ, Berrones D, Patel B, et al. The economic model of retinopathy of prematurity (EcROP) screening and treatment: Mexico and the United States. Am J Ophthalmol. 2016;168:110–21.
van den Akker-van Marle ME, van Sorge AJ, Schalij-Delfos NE. Cost and effects of risk factor guided screening strategies for retinopathy of prematurity for different treatment strategies. Acta Ophthalmol. 2015;93:706–12.
Yanovitch TL, Siatkowski RM, McCaffree M, Corff KE. Retinopathy of prematurity in infants with birth weight > or =1250 grams - incidence, severity, and screening guideline cost-analysis. J Am Assoc Pediatr Ophthalmol Strabismus. 2006;10:128–34.
Binenbaum G, Tomlinson LA, de Alba Campomanes AG, et al. Validation of the Postnatal Growth and Retinopathy of Prematurity Screening Criteria. JAMA Ophthalmology. 2019 [Epub ahead of print].
Quinn GE, Dobson V, Saigal S, Phelps DL, Hardy RJ, Tung B, et al. Health-related quality of life at age 10 years in very-low-birth-weight children with and without threshold retinopathy of prematurity. Arch Ophthalmol. 2004;122:1659–66.
Honeycutt A, Dunlap L, Chen H, Homsi G, Grosse S, Schendel D. Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment—United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:57–9.
Funding
This study was supported by the National Institutes of Health grant R01EY021137, and the Richard Shafritz Endowed Chair in Ophthalmology Research at the Children’s Hospital of Philadelphia.
G-ROP Study GroupGil Binenbaum6, Lauren A. Tomlinson6, Trang B. Duros6, Anh Nguyen6, Gui-shuang Ying7, Maureen G. Maguire7,41, Mary Brightwell-Arnold7, James Shaffer7, Yinxi Yu7, Maria Blanco7, Trina Brown7, Christopher P. Helker7, Amy Hutchinson8, Carrie Young8, Emily McCourt9, Anne Lynch9, Jennifer Cathcart9, Ashlee Cerda9, Levi Bonnell9, Tamara Thevarajah9, Gerard P. Barry10, Marilyn Fisher10, Maria V. Battaglia10, Alex M. Drach10, Kevin Hughes10, Nachammai Chinnakaruppan11, Andrew Meyer11, Christina Gogal11, Cynthia Beitler11, Lauri Centolanza11, Keith T. Moyer11, Mary Sobotor11, Pamela Donohue12, Michael X. Repka12, Jennifer A. Shepard12, Megan Doherty12, James D. Reynolds13, Erin Connelly13, Edward Cheeseman14, Kinsey Shirer14, Carol Bradham14, Allison McAlpine14, Sudeep Sunthankar14, Javaneh Abbasian15, Janet Lim15, Michael Yang16, Patricia Cobb16, Elizabeth L. Alfano16, David Rogers17, Rachel E. Reem17, Amanda Schreckengost17, Rae R. Fellows17, Kaitlyn Loh17, Madeline A. McGregor17, Thabit Mustafa17, Ivy Dean17, Rachel Miller17, Tess Russell17, Rebecca Stattler17, Sara Maletic17, Theran Jake Selph17, David Young18, Andrea Siu18, Michele Kanemori18, George Kingston18, Megan Geloneck19, Robert Feldman19, Ted Baker19, Laura Baker19, Ephrem Melese19, Kathryn Haider20, Jingyun Wang20, Elizabeth Hynes20, Edward F. Bell21, Alina V. Dumitrescu21, Jonathan M. Klein21, Gretchen A. Cress21, Avanthi S. Ajjarapu21, Kristine Berge21, Eric Boeshart21, Morgan Dorsey21, Bethany M. Funk21, Grace Hach21, Claire L. Johnson21, Kevin Kurian21, Emily Miller21, Angela C. Platt21, Christine Law22, Andrew Gissing22, Leila Khazaeni23, Jennifer Dunbar23, Kelley Hawkins23, Sharon Lee23, Lily Sung23, Carly Leggitt23, Aparna Ramasubramanian24, Rahul Bhola24, Michelle Bottorff24, Neviana Dimova24, Rachel Keith24, Laura Thomas24, Jill Anderson25, Raymond G. Areaux Jr.25, Ann Marie Holleschau25, Jordan Gross25, Andrea Kramer25, David Morrison26, Sean Donahue26, Carsyn Saige Wilkins26, Neva Fukuda26, Sandy Owings26, Scott Ruark26, R. Michael Siatkowski27, Faizah Bhatti27, Vanessa Bergman27, Karen Corff27, Kari Harkey27, Amy Manfredo27, Ashley Helmbrecht27, Shrenik Talsania27, Terri Whisenhunt27, Donny Suh28, Ann Anderson Berry28, Denise Lynes28, Kelly C. Erikson28, Gil Binenbaum29, Soraya Abbasi29, Haresh Kirpalani29, Graham E. Quinn29, Lindsay Dawson29, Lauren A. Tomlinson29, Christin Sylvester30, Kanwal Nischal30, Lauren Runkel30, Wendy S. Chen31, Deidrya Jackson31, Bradley Davitt32, Dawn Govreau32, Linda Breuer32, September Noonan32, Robert Hoffman33, Joanna Beachy33, Kelliann Farnsworth33, Katie Jo Farnsworth33, Deborah Harrison33, Ashlie Bernhisel33, Bonnie Carlstrom33, Alejandra G. de Alba Campomanes34, Yizhuo Bastea-Forte34, Lucia Rivera Sanchez34, Jacquelyn Kemmer34, Alexandra Neiman34, Sarah Sitati-Ng’Anda34, Kristina Tarczy-Hornoch35, Francine Baran35, Lauren Eaton35, Nasrin Najm-Tehrani36, Tanya Grossi36, Maram Isaac36, Robin Knighton36, Monica Ralli Khitri37, Madeline Del Signore37, Cynthia Dembofsky38, Andrew Meyer38, Karen Flaherty38, Tracey Harris38, Jamie Heeneke38, Dorothy Hendricks39, Christopher M. Fecarotta39, Alicia Olivant Fisher39, Mark Paullin39, John A. F. Zupancic40, Alejandra de Alba Campomanes41, Edward F. Bell41, Gil Binenbaum41, Pamela Donohue41, David Morrison41, Graham E. Quinn41, Michael X. Repka41, David L. Rogers41, Lauren A. Tomlinson41, Michael Yang41, Gui-shuang Ying41
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Members of the G-ROP Study Group are listed below Funding.
Supplementary information
Rights and permissions
About this article
Cite this article
Zupancic, J.A.F., Ying, Gs., de Alba Campomanes, A. et al. Evaluation of the economic impact of modified screening criteria for retinopathy of prematurity from the Postnatal Growth and ROP (G-ROP) study. J Perinatol 40, 1100–1108 (2020). https://doi.org/10.1038/s41372-020-0605-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-020-0605-5